Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)
7.10
-0.01 (-0.14%)
At close: Apr 17, 2026
HKG:2566 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 348.67 | 537.63 | 93.18 | 71.54 | 94.83 |
Short-Term Investments | 365.79 | 73.75 | 32.97 | 44.44 | 32.97 |
Cash & Short-Term Investments | 714.47 | 611.38 | 126.14 | 115.98 | 127.8 |
Cash Growth | 16.86% | 384.68% | 8.76% | -9.25% | - |
Accounts Receivable | 601.77 | 635.8 | 522.11 | 454.8 | 393.98 |
Other Receivables | - | 2.97 | 4.14 | 5.34 | 14.84 |
Receivables | 601.77 | 638.77 | 526.24 | 460.14 | 408.82 |
Inventory | 155.46 | 149.12 | 169.81 | 171.9 | 201.53 |
Other Current Assets | 11.47 | 10.7 | 17.54 | 10.74 | 9.75 |
Total Current Assets | 1,483 | 1,410 | 839.74 | 758.76 | 747.91 |
Property, Plant & Equipment | 399.84 | 354.23 | 373.56 | 385.8 | 397.93 |
Other Intangible Assets | 0.14 | 0.92 | 1.05 | 0.19 | 0.34 |
Long-Term Deferred Charges | 208.36 | 156.89 | 90.3 | 65.6 | 30.45 |
Other Long-Term Assets | 26.48 | 1 | 3.05 | 3.24 | 6.58 |
Total Assets | 2,118 | 1,923 | 1,308 | 1,214 | 1,183 |
Accounts Payable | 48.38 | 27.64 | 43.24 | 52.54 | 66.85 |
Accrued Expenses | - | 68.87 | 66.4 | 55.32 | 50.03 |
Current Portion of Long-Term Debt | 45.49 | 81.01 | 130.84 | 141.53 | 157.56 |
Current Portion of Leases | 3.45 | 0.94 | 0.77 | 0.33 | 0.31 |
Current Income Taxes Payable | 7.14 | 14.37 | 0.44 | - | - |
Current Unearned Revenue | 20.64 | 23.6 | 14.81 | 16.89 | 21.21 |
Other Current Liabilities | 207.3 | 125.25 | 91.02 | 89.31 | 104.56 |
Total Current Liabilities | 332.39 | 341.69 | 347.52 | 355.93 | 400.52 |
Long-Term Debt | 57.06 | 38.77 | 34.52 | 78.73 | 45.81 |
Long-Term Leases | 55.62 | - | 0.94 | - | 0.33 |
Long-Term Unearned Revenue | - | 6.06 | 7.27 | 7.56 | 2.5 |
Long-Term Deferred Tax Liabilities | 15.48 | 16.5 | 19.56 | 4.84 | 13.29 |
Other Long-Term Liabilities | 9.2 | 2 | - | 0.34 | 2.62 |
Total Liabilities | 469.74 | 405.01 | 409.8 | 447.4 | 465.06 |
Common Stock | 245.4 | 245.4 | 200 | 53.45 | 53.45 |
Additional Paid-In Capital | - | 1,112 | 681.43 | - | - |
Retained Earnings | - | 150.76 | 12.16 | 673.73 | 625.86 |
Comprehensive Income & Other | 1,403 | 9.6 | 4.3 | 39.01 | 38.83 |
Shareholders' Equity | 1,648 | 1,518 | 897.89 | 766.18 | 718.14 |
Total Liabilities & Equity | 2,118 | 1,923 | 1,308 | 1,214 | 1,183 |
Total Debt | 161.62 | 120.72 | 167.07 | 220.58 | 204 |
Net Cash (Debt) | 552.85 | 490.66 | -40.93 | -104.6 | -76.2 |
Net Cash Growth | 12.67% | - | - | - | - |
Net Cash Per Share | 2.25 | 2.40 | -0.20 | -0.52 | -0.38 |
Filing Date Shares Outstanding | 245.4 | 245.4 | 200 | 200 | 200 |
Total Common Shares Outstanding | 245.4 | 245.4 | 200 | 200 | 200 |
Working Capital | 1,151 | 1,068 | 492.22 | 402.82 | 347.39 |
Book Value Per Share | 6.72 | 6.19 | 4.49 | 3.83 | 3.59 |
Tangible Book Value | 1,648 | 1,517 | 896.84 | 765.99 | 717.79 |
Tangible Book Value Per Share | 6.72 | 6.18 | 4.48 | 3.83 | 3.59 |
Buildings | - | 276.41 | 274.03 | 271.85 | 268.73 |
Machinery | - | 319.44 | 307.57 | 290.15 | 271.78 |
Construction In Progress | - | 0.24 | 0.69 | 1.85 | 0.36 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.